GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » Quality Rank

CardieX (ASX:CDX) Quality Rank


View and export this data going back to 2005. Start your Free Trial

What is CardieX Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

CardieX Quality Rank Related Terms

Thank you for viewing the detailed overview of CardieX's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


CardieX (ASX:CDX) Business Description

Traded in Other Exchanges
N/A
Address
55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000
CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.